Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Karyopharm Therapeutics (KPTI) over the last 11 years, with Q4 2025 value amounting to $230299.0.

  • Karyopharm Therapeutics' Gains from Sales and Divestitures fell 9054.94% to $230299.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $230299.0, marking a year-over-year decrease of 9054.94%. This contributed to the annual value of $230299.0 for FY2025, which is 9054.94% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Gains from Sales and Divestitures stood at $230299.0, which was down 9054.94% from $2.4 million recorded in Q4 2024.
  • In the past 5 years, Karyopharm Therapeutics' Gains from Sales and Divestitures ranged from a high of $957.7 million in Q4 2022 and a low of $230299.0 during Q4 2025
  • Its 5-year average for Gains from Sales and Divestitures is $192.4 million, with a median of $1.1 million in 2023.
  • Per our database at Business Quant, Karyopharm Therapeutics' Gains from Sales and Divestitures surged by 19932321.59% in 2022 and then crashed by 9989.03% in 2023.
  • Karyopharm Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $480249.0 in 2021, then skyrocketed by 199323.22% to $957.7 million in 2022, then crashed by 99.89% to $1.1 million in 2023, then skyrocketed by 132.04% to $2.4 million in 2024, then tumbled by 90.55% to $230299.0 in 2025.
  • Its last three reported values are $230299.0 in Q4 2025, $2.4 million for Q4 2024, and $1.1 million during Q4 2023.